HealthQuill Articles by: HealthQuill
The full year 2023 is set to be the warmest on record with global temperatures rising 1.4 degrees Celsius above pre-industrial levels, as the UN chief called on COP28 nations to set “clear expectations” for climate goals and invest in their implementation. Image Credit: UN
Climate Health Pharma

Record global heat ‘sending shivers down the spines of world leaders’: UN

HQ Team December 1, 2023: The full year 2023 is set to be the warmest on record with global temperatures rising 1.4 degrees

Read More
Mosquitoes by the evening. Image Credit: Wolfgang Hasselmann on Unsplash
Climate Drugs Pharma

WHO global malaria strategy ‘off track by a wide margin’

HQ Team November 30, 2023: The Covid-19 pandemic significantly disrupted malaria services, leading to a surge in both incidence and mortality rates, exacerbating

Read More
AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to acquire ImmunoGen, Inc., for $10.1 billion. Image Credit: AbbVie
Drugs Health Pharma

AbbVie to buy Immunogen for $10.1b to expand solid tumour market

HQ Team November 30, 2023: AbbVie Inc., operating in therapeutic areas such as immunology, oncology, neuroscience, and eye care, announced a pact to

Read More
Exposure to typical levels of traffic-related air pollution can diminish brain function within hours, according to researchers at the University of British Columbia.
Climate Health Medical

Commute-linked air pollution has alarming Impact on blood pressure

HQ Team November 30, 2023: Rush hour traffic is an everyday reality for most city dwellers. Adding to the frustration of being stuck

Read More
The COP28 has reached an agreement to operationalise a fund, known as ‘loss and damage’ to aid developing nations to mitigate the adverse effects of climate change.
Climate Health Pharma

‘Loss and damage’ climate mitigation fund gets going at COP28

HQ Team November 30, 2023: The COP28 has reached an agreement to operationalise a fund, known as ‘loss and damage’ to aid developing

Read More
Drugs Health Medical

Exercise, a promising approach to tackle postpartum depression

HQ Team November 30, 2023: Postpartum depression is a common psychological affliction following childbirth and affects 17.22% of the world population. Postpartum depression

Read More
The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023 was received with surprise by many. Compared to cereals like rice and wheat, millets were not given much significance and now they are considered as super food with high nutritive value.
Drugs Health Pharma

Opinion: Feast for G20 leaders, benefits of millets exceed rice, wheat

By Dr. K. Leelamoni November 30, 2023: The move to serve Indian millet-based food, to G20 leaders in New Delhi in September 2023

Read More
The first human case of a new swine flu variant in the UK has been detected by the Health Security Agency during a polymerase chain reaction testing after the individual had respiratory illness.
Drugs Health Pharma

First new strain of swine flu detected in UK, probe on to track virus origins

HQ Team November 29, 2023: The first human case of a new swine flu variant in the UK has been detected by the

Read More
The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global health agency reported an 8.9% rise in global prevalence in cases arising in the UK, France and Sweden.
Drugs Health Pharma

Omicron mutant BA.2.86 reclassified as ‘variant of interest’ by WHO 

HQ Team November 29, 2023: The WHO has reclassified the Covid-19 virus Omicron BA.2.86 mutation as a “variant of interest” after the global

Read More
The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies in patients who received treatment.
Drugs Health Pharma

FDA probing T cell cancer therapies of Gilead Sciences, Novartis, J & J

HQ Team November 29, 2023: The USFDA is probing cancer therapies of Gilead Sciences, Johnson & Johnson and Novartis following reports of malignancies

Read More